Name: Cancer Prevention Pharmaceuticals Inc. - BioCentury Company Profiles - BCIQ
Creator: Biocentury

signInButton

SIGN IN

Find partnering and investment opportunities, uncover and track competitive threats, dive into a company's financing and deal history, its pipeline and molecular targets of interest, and much more. Please note, you are viewing a free version of BCIQ, BioCentury's advanced business intelligence database for the biopharma industry. Request a trial to unlock the full value of BCIQ.

REQUEST A FREE TRIAL

AcquiredOrMerged

Company profiles have been archived if there have been no financings, deals or product updates in BCIQ in the last five years, or the company is out of business.

If you believe a company has been archived in error, please contact us at 

Company profiles have been archived if there have been no financings, deals or product updates in BCIQ in the last five years, or the company is out of business.\nIf you believe a company has been archived in error, please contact us at \nsupport@biocentury.com\n.

Cat-H(AcquiredorMerged)

Historical deals and financings can be found by searching the organization's name in the BCIQ <DEALS> and <FINANCING> Modules.

Default (Company Type Blank)

CategoryHDefault (Company Type Blank)

NonBioPharma

Biopharma related deals can be found by searching the organization's name in the <DEALS> Module.

Cat-H(NonBioPharma)

Biopharma related deals can be found by searching the organization's name in the <DEALS> Module.\n

Cancer Prevention Pharmaceuticals Inc.

June 21 Clinical Quick Takes: Melanoma miss for Exelixis/Genentech combo; plus Progenics, Turning Point, Gracell

Mallinckrodt acquiring Sucampo

Mallinckrodt acquiring Sucampo

Cancer Prevention starts Phase II of CPP-1x to prevent gastric cancer

IDMC recommends continuation of Cancer Prevention's Phase III FAP trial

Right place, right time

Cancer Prevention Pharmaceuticals withdraws IPO

Therapeutics: Spermidine/spermine N1-acetyltransferase 1 (SAT1; SSAT); ornithine decarboxylase (ODC)

Cancer Prevention Pharmaceuticals amends IPO

Cancer Prevention Pharmaceuticals amends IPO